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Background: The aim of this study was to assess one-year implant survival after lateral window sinus augmenta-
tion using PRGF combined with various bone grafting materials.
Material and Methods: This was a retrospective chart review and radiographic analysis of patients that had under-
gone lateral window sinus augmentation with PRGF and had dental implants placed at least 6 months post aug-
mentation. All implants included were followed up for at least one year after placement. Demographic, sinus and 
implant related characteristics (residual ridge height, sinus membrane perforation, type of graft material, implant 
length and width and ISQ at placement) were analyzed.
Results: A total of 31 patients with 39 sinus augmentations and 48 implants were included. The mean follow up 
was 22.8 ± 9.9 months. Implant survival was 95.8%, with 2 implants overall failing. Among all the variables as-
sessed, the only one found to be associated with an increased risk for implant failure was the use of xenograft as 
bone grafting material in the sinus.
Conclusions: Within the limitations of this study, dental implants placed in maxillary sinuses grafted with PRGF 
in combination with bone grafting materials, exhibit high implant survival rates after at least one year follow up.
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Introduction
Implant supported dental reconstruction in the posterior 
maxilla can be challenging, primarily due to insufficient 
alveolar ridge dimensions following loss of teeth and 
subsequent maxillary sinus pneumatization. Sinus floor 
augmentation, through the lateral window approach, has 
been successfully implemented to increase bone dimen-
sions and allow for dental implant placement with high 
long-term survival rates (1). A variety of bone grafting 
materials have been successfully used for sinus augmen-
tation including autogenous bone, xenografts, allografts 
and alloplasts. A recent study on bone quality outcomes 
following use of different grafting materials, reported 
that autogenous bone resulted in the highest amount of 
new bone formation and lowest amount of residual graft 
material compared to other options, whereas no differ-
ence was noted between allografts, xenografts and allo-
plasts (2). However, disadvantages associated with use of 
autogenous bone, including morbidity, limited availabil-
ity and high volumetric changes (2), promoted the use of 
other biomaterials, often combined with platelet concen-
trates in an effort to enhance the regenerative outcome 
in maxillary sinus augmentation. Plasma rich in Growth 
factors (Endoret® PRGF) is an autologous blood derived 
product that was originally developed by Anitua et al. (3), 
in an effort to enhance wound healing and promote tissue 
regeneration when used in different intraoral bone graft-
ing procedures. PRGF is based on a single centrifugation 
technique and requires the conjugation of anticoagulants 
with the freshly collected blood as well as the subsequent 
addition of calcium chloride in order to allow for the 
formation of a provisional adhesive matrix (4). Theoreti-
cally, the enmeshment of a supraphysiologic concentra-
tion of platelets within the matrix allows for the secretion 
of high concentration of growth factors including VEGF, 
PDGF and IGF which can enhance wound healing 
through stimulation of re-epithelialization, angiogenesis 
and extracellular matrix formation (5). In contrast to other 
platelet concentration technologies  available, the PRGF 
preparation protocol aims at eliminating leukocytes in an 
effort to avoid any pro-inflammatory effects associated 
with them and allows for it to be used in diverse forms of 
clinically applicable products, such as clots, fibrin mem-
brane and liquid, derived from the different fractions of 
the plasma column upon centrifugation(5). PRGF has 
been used in maxillary sinus augmentation in combina-
tion with various bone grafting materials with favorable 
outcomes in terms of new vital bone formation and post-
operative swelling and pain (6-8). There is limited evi-
dence though regarding survival rates of implants placed 
on maxillary sinuses grafted with PRGF (9). The aim of 
the present retrospective study was to assess implant sur-
vival with at least one year follow up after lateral window 




This study was a retrospective chart review and analy-
sis of corresponding cone beam computed tomography 
(CBCT) scans as well as periapical radiographs. The 
study protocol was approved by the Louisiana State 
University Health Sciences Center – New Orleans In-
stitutional Review Board (IRB # 9727). Patients in-
cluded in the study, were treated in the Department of 
Periodontics Postgraduate Clinic at LSUHSC School of 
Dentistry (SOD) from July 1st, 2010 to June 30th, 2016. 
Charts of patients along with Cone Beam Computed 
Tomography (CBCT) scans were carefully reviewed 
to identify individuals that conformed to the following 
inclusion criteria: 1) History of Lateral Window Sinus 
Augmentation with PRGF in combination with bone 
grafting materials; 2) CBCT scans available before and 
6 months after sinus augmentation; 3) Dental implants 
placed in the grafted maxillary sinuses at least 6 months 
after augmentation and followed up radiographically for 
at least one year after implant placement.
All patients reviewed had previously undergone sinus 
floor augmentation surgery performed using a lateral 
window approach (10), after radiographic evaluation 
with a CBCT (Fig. 1).
Fig. 1: Lateral wall osteotomy with intact Schneiderian membrane.
Each patient had undergone a blood draw for PRGF 
preparation as per the manufacturer’s protocol (PRGF®-
Endoret® BTI Biotechnology Institute) (7). Briefly, 
blood was taken from patients by venipuncture before 
surgery into tubes containing 3.8% sodium citrate as 
anticoagulant. PRGF was prepared by centrifugation at 
460g for 8 minutes at room temperature.  Plasma not 
including the buffy coat above red blood cells, was pi-
petted out in two fractions. Fraction 1, closest to the red 
and white blood cell containing sediment, was mixed 
with calcium chloride on a dose dependent quantity and 
then mixed with a bone graft material (Fig. 2).
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The mix was incubated at 37C until a gel like consis-
tency was formed. The product was then used as a graft 
material into the sinus cavity (Fig. 2). Fraction 2, imme-
diately above fraction 1, was also mixed with calcium 
chloride on a dose dependent manner and the produced 
material was used as a membrane. The PRGF membrane 
was then placed over a collagen membrane covering the 
lateral window, prior to flap closure (Fig. 3).
bone height prior to implant placement. Dental implants 
were placed following a 1 stage or 2-stage protocol. 
Implant stability was recorded using Implant stabil-
ity Quotient (ISQ). After a healing period of at least 3 
months, second stage surgery was completed with an-
other ISQ recording and the patient was subsequently 
referred back for continuation of restorative treatment.
- Data collection
The following information was collected for each pa-
tient: demographic data (gender and age) and smoking 
habits at the time of surgery. Surgery related parame-
ters recorded included (i) type of graft material that was 
mixed with PRGF (xenograft, allograft or combination), 
(ii) type of implant placed (brand, length, width), (iii) 
implant stability measured with implant stability quo-
tient (ISQ) at the time of implant placement and stage 2 
surgery and (iv) sinus membrane perforation at the time 
of surgery (Yes/No). 
- CBCT Scan Analysis
All CBCT images were previously obtained with an 
iCat Next Generation XYZ Slice View Tomograph (Im-
aging Sciences International LLC, Hatfield, PA). For all 
CBCT images, a limited field of view (FOV) of 4x4 cm, 
8x8 cm, 10x16 cm was selected. CBCT images were 
evaluated by a single provider (M.F.) in axial, sagittal 
and coronal planes using the iCatVisionTM software, 
version 1.8.1.10 (Imaging Sciences International LLC, 
Hatfield, PA). CBCT images were analyzed using a 13-
inch MacBook Pro with Retina display with a resolution 
of 1,440x900 (Apple Inc.) The following variables were 
assessed pre-operatively: 
a. Residual bone height (RBH): Distance between al-
veolar bone crest and inferior border of the sinus at the 
area of the least amount of residual bone. 
b. Thickness of the sinus membrane: Distance between 
inferior border of the sinus and mucosal surface on the 
planned area of sinus augmentation. 
c. Morphology of sinus membrane was evaluated and 
classified according to criteria modified from Soik-
konen and Ainamo (11) : 1) healthy sinus membrane 
with no thickening (<2mm); 2) flat: shallow thickening 
without well-defined outlines; 3) semispherical: thick-
ening with well-defined outlines rising in an angle of 
> 30 degrees from the floor of the walls of the sinus; 4) 
mucocele-like: complete opacification of the sinus; 5) 
mixed-flat and semispherical thickening.
d. Presence or absence of septae
e. Presence or absence of alveolar antral artery (anasto-
mosis of posterior superior alveolar artery and infraor-
bital artery)
At 6 months after sinus augmentation surgery, bone 
height at the CBCT was measured again to assess bone 
gain, with an effort made to make the measurements 
at the same site where the pre-operative measurements 
were made.
When appropriate, PRGF membranes were also used 
to repair sinus membrane perforations.  The grafting 
materials that were used for all sinus augmentations (in 
combination with PRGF) included either bovine anor-
ganic bone (Bio-Oss®, Geistlich Biomaterials, Wolhu-
sen, Switzerland), cancellous bone allograft (Puros®, 
Zimmer Biomet, Carlsbad, CA) or a combination of 
both graft materials. None of the patients had implant 
placed simultaneously with maxillary sinus augmenta-
tion. Post-surgically, all patients received antibiotic cov-
erage along with appropriate analgesics, anti-inflamma-
tory medications and Chlorhexidine Rinse 0.12%. All 
patients received new CBCT scans approximately six 
months post maxillary sinus augmentation, to assess 
Fig. 2: Placement of the xenograft mixed with PRGF into the sinus.
Fig. 3: Lateral wall covered with PRGF membrane. The same 
PRGF membrane was used to seal intra-operative sinus membrane 
populations.
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- Implant survival and success
Periapical radiographs taken at the time of implant 
placement, implant uncovery, implant restoration and 
at least 1 year follow up post placement were reviewed 
by a single individual (M.F.). Misch criteria for success 
(12) were used to assess implant outcomes at follow-ups 
measuring for radiographic bone loss: I. Success (opti-
mum health): <2 mm radiographic bone loss from initial 
surgery; II. Satisfactory survival: 2–4 mm radiographic 
bone loss; III. Compromised survival: Radiographic 
bone loss >4 mm (less than 1/2 of implant body); IV. 
Failure: Radiographic bone loss >1/2 length of implant. 
- Statistical analysis
The primary outcome was implant survival (a binary 
variable). A survival analysis was planned but not per-
formed due to the very small number of events (implant 
failure). For the same reason, a logistic regression model 
that jointly considered all risk factors together could not 
be performed. To explore risk factors that are signifi-
cantly related with the implant survival, we performed 
a two-sample t-test for each continuous risk factor (Age, 
ISQ and Residual ridge height) and a Fisher’s exact test 
for each binary or categorical factor (sex, smoking, 
Schneiderian membrane perforation, bone graft mate-
rial, implant length, implant diameter and stage place-
ment). The significance level was set at 0.05. All analy-
ses were performed using SAS version 9.4.
Results
A total of 31 patients (13 male, 22 female) with a mean 
age of 61.92 ± 7.45 (range 42–73 y/o) were included with 
29% of them being current smokers. A total of 39 max-
illary sinus augmentations were completed, with a total 
of 48 implants placed. Table 1 shows the demographic 
and maxillary sinus related characteristics. In general, 
residual ridge height was 3.9mm ± 1.66 with a mean si-
nus membrane thickening of 1.09mm ± 1.81. 10% of the 
sinuses had septae as identified in the CBCT scans and 
the alveolar antral artery was noted in 4 cases (10%).
The majority of the sinuses (69%) showed no thickening 
of the Schneiderian membrane, whereas 26% presented 
a flat shallow thickening with well-defined borders. 
During sinus augmentation, 36% of the sinuses had per-
foration of the Schneiderian membrane. Table 2 shows 
characteristics of the implants placed in the augmented 
sinuses.
Total patients 31
Age at first visit 61.92 ± 7.45
Gender (men) 13 (41.93%)
Smoking 9 (29.03%)
N of maxillary sinuses 39
Residual ridge before MSA 3.9 ± 1.66
SM thickening (mm) 1.09 ± 1.81
Septa present 4/39 (10%)





Mixed flat/semispherical 1 (2%)
Mucocele-type 0 (0%)




Xenograft + Allograft 2 (5%)
Sinus Membrane Perforations 14 (36%)
Residual ridge after MSA 15.64 ± 3.42
Bone height increase 11.73 ± 3.32
N of implants 48
Implant Brand
Straumann SLA® Bone level 1 (2%)
NobelReplace® Tapered 6 (12.5%)
AstraTech Osseospeed® TX 3 (6.25%)
Biohorizons® Tapered Internal Plus 5 (10.5%)
Zimmer Tapered Screw-vent® 30 (62.5%)








2-stage implant placement 44/48 (92%)
ISQ at placement 73.46 ± 8.06
ISQ at uncovery 78.44 ± 6.97
% of implant survival 95.8% (46/48)
% of implant success (Misch criteria I) 93.75% (45/48)
Follow up (months) 22.8 ± 9.9
Implants were followed up for a mean of 22.8±9.9 
months.  Overall, two implants failed (implant survival 
rate 95.8%), one of which as an early failure due to in-
ability to establish osseointegration and the other as 
a late failure due to advanced peri-implantitis. Based 
on the one-year post-placement radiographic evalua-
tion, implant success rate (Misch Criteria I) (12) was 
93.75%. The majority of the implants placed were Zim-
mer Tapered Screw-vent® (62.5%) and the remaining 
were almost equally distributed among five other im-
plant brands NobelReplace® Tapered, AstraTech Os-
seospeed® TX, Straumann SLA® Bone level, BioMet 
3i Osseotite®, Biohorizons® Tapered Internal Plus. For 
the majority of the implants, an increase on ISQ mea-
Table 1: Distribution of demographic and maxillary sinus related 
characteristics..
Table 2: Distribution of MSA/Implant related characteristics.
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surements was noted from placement to stage 2 implant 
exposure, with an average increase from 73.46 ± 8.06 to 
78.44 ± 6.97. Among all the variables assessed, the only 
one found to be associated with an increased risk for 
implant failure was the use of xenograft as bone graft-
ing material in the sinus, either alone or in combination 
with an allograft (p=0.0275). None of the other factors 
including age, sex, smoking, ISQ at placement, residual 
ridge height, perforation of the sinus membrane, implant 
length, implant diameter or 1 vs. 2 stage implant place-
ment were associated with implant survival (Table 3).
new bone when compared to bovine bone (15). How-
ever, when considering non-comparative studies, they 
reported that it was not possible to detect any signifi-
cant difference among examined biomaterials, postulat-
ing that in the presence of all conditions allowing for 
blood clot stability, the space below the Schneiderian 
membrane can become populated by osteoprogenitor 
cells that induce bone regeneration irrespective of the 
biomaterial used to fill the space (15). Studies have even 
advocated no use of bone substitutes in sinus floor el-
evations and allowing the site to fill in with only blood 
clot, with implants acting as a tent against the elevated 
Schneiderian membrane, reporting high implant sur-
vival rates (16).
Whether the selection of bone grafting material has any 
effect on dental implant survival has also been assessed. 
Nkenke et al. in a systematic review attempted to ad-
dress whether the use of autogenous bone is superior to 
bovine bone in terms of implant survival and reported 
that the type of graft did not seem to be associated with 
implant survival rates and questioned the use of autoge-
nous bone due to associated morbidity (17). In the pres-
ent study, the only factor associated with implant failure 
was the use of xenograft as bone grafting material in 
the sinus. However, this finding contradicts current evi-
dence reporting that the type of bone graft material in 
the sinus has no effect on implant survival (17). This 
finding may be attributable to the fact that the type of 
bone graft material used was not randomly assigned to 
the patients. 
More recently, in an effort to enhance regenerative out-
comes in maxillary sinus augmentation without the use 
of autogenous bone, bone grafting materials have been 
combined with autologous platelet concentrates, due to 
their high concentration of platelet derived growth fac-
tors. A variety of autologous preparation protocols have 
been introduced including Platelet-rich Plasma (PRP) 
(18), Platelet-rich Fibrin (PRF) (19) , and Plasma-rich 
in Growth factors (PRGF) (3), with a wide range of out-
comes reported. Lemos et al. (20) in a systematic re-
view, found no influence of PRP on bone formation and 
implant survival when used in maxillary sinus augmen-
tation. Similarly, Dragonas et al. (21) in another system-
atic review, reported that the use of L-PRF in maxillary 
sinus augmentation was not associated with more fa-
vorable outcomes, in terms of new bone formation and 
soft tissue healing. With regards to the use of PRGF for 
maxillary sinus grafting, a recent review reported that 
its use was associated with positive outcomes for soft 
tissue healing and postoperative symptoms, however, 
the outcomes on new bone formation were conflicting, 
with one study reporting higher % of NBF in PRGF 
treated sites and two studies no difference in PRGF vs. 
control sites (22).
Overall however, there is limited evidence regard-
ing implant survival in maxillary sinuses grafted with 
p-value
Age at first visit 0.3277
Gender 0.5328
Smoking 0.4521
Sinus Membrane Perforation 1.000
Type of Graft 0.0275*
ISQ at placement 0.2881
Residual ridge height before MSA 0.1039
Implant length 0.2048
Implant width 0.5027
1 vs 2 stage implant placement 0.1995
Table 3: Association of patient characteristics with implant survival.
Discussion
This retrospective study reports an implant survival 
rate of 95.8% for implants placed at least 6 months af-
ter maxillary sinus augmentation with bone graft plus 
PRGF and with at least one year follow up, in a univer-
sity setting. This outcome is similar to survival rates 
of dental implants placed in grafted maxillary sinuses 
as reported in previously published systematic reviews 
(1,13). Specifically, Corbella et al. in a systematic re-
view of 29 studies with at least 3 year implant follow up 
post lateral sinus augmentation using a variety of bone 
grafting materials, reported implant survival varying 
from 75.57% to 100% with the majority of the included 
studies reporting survival rates over 90% (13). In an-
other systematic review Del Fabbro et al. reported im-
plant survival of 93.7% after lateral sinus augmentation, 
with the majority of the failures occurring within the 
1st year (1).
As a wide range of bone grafting materials have been 
used with good success in maxillary sinus augmentation 
procedures, the ideal grafting material is still debated in 
the literature. The amount of new bone formation (NBF) 
through histomorphometric analysis has been consid-
ered one important parameter to assess when evaluating 
success of maxillary sinus augmentation (14). Corbella 
et al. in a meta-analysis of histomorphometric outcomes 
following maxillary sinus augmentation reported that 
autogenous bone could lead to a higher percentage of 
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PRGF. Khouly et al. (9) reported 90% implant survival 
with a mean follow up of 7.2 years in 100 augmented 
sinuses with PRGF, with residual crestal bone of < 3mm 
and immediate loading being associated with increased 
risk for implant failure. Torres et al. (23) reported 98.6% 
of implant success after a 2 year follow up, in sites that 
were grafted with bovine bone and PRGF, with no dif-
ference when compared with implants placed in sinuses 
grafted with bovine bone alone. Similarly, Anitua et al. 
(7) reported 100% implant survival in sites grafted with 
PRGF after a mean follow up period of 33±7 months.
In the present study a high implant survival rate (95.8%) 
was noted despite the surgeries being completed by 
periodontics residents in training. According to a recent 
meta-analysis, surgical experience significantly affect-
ed implant failure rates (24). The high implant survival 
rate noted in this cohort could be attributed to a number 
of factors. First, all patients were assessed for presence 
of sinus pathologies through pre-surgical CBCT evalu-
ation and referred for ENT consultation as needed. Prior 
to sinus augmentations, 90% of the patients radiograph-
ically presented with either sinus membrane with no 
thickening or flat shallow thickening with well-defined 
outlines. In 8% of our cases where semispheric sinus 
membrane morphology was noted (usually indicative 
of mucous retention cyst/antral pseudocyst), all were 
less than 5mm in height. Moreover, all implants were 
placed at least 6 months post sinus augmentation, with 
no cases of simultaneous implant placement, which has 
been reported as a potential risk factor, especially in the 
presence of minimal residual bone height (25). All im-
plants also were placed with good primary stability as 
noted by the ISQ measurements taken at the time of im-
plant placement (73.46 ± 8.06) which increased during 
the healing period (78.44 ± 6.97). ISQ values ranging 
from 57 to 82 denote appropriate implant stability and a 
complete process of osseointegration (26). 
Perforation of the sinus membrane did not seem to be 
associated with implant failure in this study. A recent 
systematic review on 58 included studies reported that 
an intraoperative sinus membrane perforation could in-
crease the risk of implant failure after sinus augmen-
tation surgery (27). The authors commented that this 
positive relationship could be explained by the event 
of displacement of bone particles through the perfora-
tion, even in the event of membrane repair, resulting in 
chronic infection, bone graft resorption and reduction 
in bone formation (27). We cannot truly assess whether 
the use of PRGF as a membrane to repair sinus mem-
brane perforation or mixed with the bone grafting ma-
terial may have reduced complications associated with 
perforations in our study. However, the sticky consis-
tency of the bone graft when mixed with PRGF may 
improve its graft-handling properties and help with 
reducing its displacement through the perforation (28). 
Also, the use of a PRGF membrane has been previously 
reported to assist in sealing membrane perforations dur-
ing endodontic surgery as well as crestal and lateral si-
nus augmentations (8,29,30). Whether the use of PRGF 
contributed to the high implant survival rate noted in 
this study irrespective of the 36% incidence of mem-
brane perforations cannot be assessed.
The study has some limitations due to the nature of it be-
ing a retrospective collection of data. First, the surgeries 
were completed by different clinicians under training 
which increases surgical variability and reduces treat-
ment consistency. Also the number of individuals and 
sinus augmentations included in this analysis was rela-
tively small, which did not allow us to perform a logistic 
regression analysis that could have simultaneously con-
sidered all risk factors.
Conclusions
Within the limitations of this study, it can be concluded 
that dental implants placed in maxillary sinuses grafted 
with bone graft combined with PRGF, exhibited high 
implant survival rates after at least one-year follow up. 
The extent of PRGF contribution to the high implant 
survival rate though, needs to be assessed through ran-
domized controlled trials, where the presence of controls 
(non-PRGF grafted sinuses) would further elucidate the 
effects of this blood-derived platelet concentrate.
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